12.19
-0.12(-0.97%)
Currency In USD
| Previous Close | 12.31 |
| Open | 12.33 |
| Day High | 12.66 |
| Day Low | 12 |
| 52-Week High | 16.91 |
| 52-Week Low | 7.95 |
| Volume | 106,524 |
| Average Volume | 188,859 |
| Market Cap | 606.68M |
| PE | -3.68 |
| EPS | -3.31 |
| Moving Average 50 Days | 12.95 |
| Moving Average 200 Days | 12.61 |
| Change | -0.12 |
If you invested $1000 in Mineralys Therapeutics, Inc. (MLYS) since IPO date, it would be worth $661.06 as of January 02, 2025 at a share price of $12.19. Whereas If you bought $1000 worth of Mineralys Therapeutics, Inc. (MLYS) shares 1 year ago, it would be worth $1,404.38 as of January 02, 2025 at a share price of $12.19.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Mineralys Therapeutics to Participate in Upcoming Investor Conferences
GlobeNewswire Inc.
Nov 05, 2024 9:05 PM GMT
RADNOR, Pa., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by
Mineralys Therapeutics to Announce Third Quarter 2024 Financial Results and Host Conference Call on Monday, November 11, 2024
GlobeNewswire Inc.
Nov 04, 2024 9:05 PM GMT
RADNOR, Pa., Nov. 04, 2024 (GLOBE NEWSWIRE) -- Mineralys Therapeutics, Inc. (NASDAQ: MLYS), a clinical-stage biopharmaceutical company focused on developing medicines to target hypertension, chronic kidney disease (CKD) and other diseases driven by
Mineralys Therapeutics Completes Enrollment Ahead of Schedule in Launch-HTN, the Second Pivotal Trial of Lorundrostat for the Treatment of Hypertension
GlobeNewswire Inc.
Oct 30, 2024 12:00 PM GMT
– Topline data now anticipated in mid first half of 2025 – – Management to host virtual KOL event today to discuss the unmet need in hypertension, as well as a review of the ongoing pivotal clinical program for lorundrostat in hypertension – RADNOR,